Persistent hypercoagulability in dogs envenomated by the European adder (Vipera berus berus)

PLoS One. 2022 Feb 18;17(2):e0263238. doi: 10.1371/journal.pone.0263238. eCollection 2022.

Abstract

Background: Envenomation by the European adder, Vipera berus berus (Vbb), is a medical emergency. The overall in vivo haemostatic effects of pro- and anticoagulant components in Vbb venom, and the downstream effects of cellular injury and systemic inflammation, are unclear.

Objectives: To longitudinally describe the global coagulation status of dogs after Vbb envenomation and compare to healthy controls. A secondary aim was to investigate differences between dogs treated with and without antivenom.

Methods: Citrated plasma was collected at presentation, 12 hours (h), 24 h, 36 h and 15 days after bite from 28 dogs envenomated by Vbb, and from 28 healthy controls at a single timepoint. Thrombin generation (initiated with and without exogenous phospholipids and tissue factor), thrombin-antithrombin (TAT)-complexes and the procoagulant activity of phosphatidylserine (PS)-expressing extracellular vesicles (EVs), expressed as PS-equivalents, were measured.

Results: At presentation the envenomated dogs were hypercoagulable compared to controls, measured as increased thrombin generation, TAT-complexes and PS-equivalents. The hypercoagulability decreased gradually but compared to controls thrombin generation and PS-equivalents were still increased at day 15. The discrepancy in peak thrombin between envenomated dogs and controls was greater when the measurement was phospholipid-dependent, indicating that PS-positive EVs contribute to hypercoagulability. Lag time was shorter in non-antivenom treated dogs, compared to antivenom treated dogs <24 h after envenomation.

Conclusions: Hypercoagulability was measured in dogs up to 15 days after Vbb envenomation. Dogs treated with antivenom may be less hypercoagulable than their non-antivenom treated counterparts. Thrombin generation is a promising diagnostic and monitoring tool for Vbb envenomation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antithrombin III
  • Antivenins / therapeutic use*
  • Case-Control Studies
  • Dog Diseases / etiology*
  • Dog Diseases / therapy*
  • Dogs
  • Female
  • Immunologic Factors / therapeutic use*
  • Inflammation / blood
  • Inflammation / etiology
  • Inflammation / therapy
  • Inflammation / veterinary
  • Longitudinal Studies
  • Male
  • Peptide Hydrolases / blood
  • Snake Bites / complications*
  • Thrombin / analysis
  • Thrombophilia / blood
  • Thrombophilia / etiology*
  • Thrombophilia / therapy
  • Thrombophilia / veterinary*
  • Treatment Outcome
  • Viper Venoms / immunology
  • Viperidae*

Substances

  • Antivenins
  • Immunologic Factors
  • Viper Venoms
  • antithrombin III-protease complex
  • Antithrombin III
  • Peptide Hydrolases
  • Thrombin

Grants and funding

HH received funding for this study from: - the Agria and SKK Research Fund for Pets, Grant number N2018-0014,www.skk.se/sv/Agria-SKK-Forskningsfond. - The Raagholt Foundation, www.raagholtstiftelsen.no - Dyrlege Smiths Legat The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.